Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2007

Medarex and Compugen Partner on Mab-Based Therapeutics in Oncology and Autoimmune Diseases

  • Medarex and Compugen are partnering to develop Mab-based therapeutics for oncology and autoimmune diseases.
    Compugen expects to utilize its antibody-target discovery engine to identify drug targets. Medarex plans to develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System®.

    The collaboration also provides that Compugen may independently pursue diagnostic applications involving certain antibodies and targets.

    Under the terms of the agreement, Medarex and Compugen plan to share discovery, development, and commercialization responsibilities as well as revenues generated from the sale of any therapeutic products resulting from this collaboration.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »